Advanced Cell Technology Provides Corporate Update About IND Plans

WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”) (OTC: ACTC) provided a corporate update today. The Company announced that it has accelerated its efforts to file an IND for its retinal pigment epithelium (RPE) cells program for the treatment of diseases of the eye in light of today’s decision by the U.S. Food and Drug Administration to grant clearance for a stem cell company to begin trials for the world's first study of a human embryonic stem cell-based therapy for people. The Company is close to securing the necessary funding which would allow it to make the requisite filings during the summer of this year. An IND filing is required in order to commence clinical trials in humans.